Rocenib 5mg Tablet

Rocenib 5mg Tablet is used to treat moderate to severe rheumatoid arthritis. It helps decrease pain, tenderness and swelling in the joints by reducing inflammation. It also helps slow the progression of bone and joint damage.

Rocenib 5mg Tablet may be prescribed by itself or in combination with another medicine. The tablets can be taken with or without food and it is best to take them at the same time each day. Your dose will depend on your condition and what other medicines you are taking. You should use it as your doctor tells you to. Do not stop taking this medicine unless your doctor tells you to, because your condition could get worse.

The most common side effects of Rocenib 5mg Tablet include throat and nose infections, nausea and viral infection. You may also get cold sores, feel sick or have symptoms of a cold like stuffy nose, sneezing and sore throat. There are other less common side effects, some of them serious, including blood clots and tears in the stomach or intestine wall. These need urgent medical attention. If you have any worries about side effects, talk to your doctor.

You may need blood tests before you are given this medicine and you should not start taking it if you have any kind of infection. Make sure you talk to your doctor before starting treatment if you have, or have ever had, tuberculosis, shingles, kidney or liver disease, hepatitis B or C, or blood clots in your legs or lungs. Rocenib 5mg Tablet can make you more likely to get infections or may worsen any current infections so avoid contact with people who have things you might catch (such as chickenpox, measles, flu). This medicine is not suitable for children under 18 years old and you should not use it if you are pregnant or breastfeeding, unless your doctor feels the benefit is greater than the risk. Your doctor may need to examine you on a regular basis.

• Rheumatoid arthritis

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Jakauto

• Headache
• Diarrhea
• High blood pressure
• Rash
• Pneumonia
• Bronchitis (inflammation of the airways)
• Tuberculosis
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Urinary tract infection
• Cellulitis
• Herpes zoster
• Diverticulitis
• Appendicitis
• Anemia (low number of red blood cells)
• Cough
• Abdominal pain
• Vomiting
• Nausea
• Stomach inflammation
• Dyspepsia
• Joint pain
• Fever
• Peripheral edema
• Fatigue

This medicine is for external use only. Use it in the dose and duration as advised by your doctor. Check the label for directions before use. Clean and dry the affected area and apply the gel. Wash your hands after applying, unless hands are the affected area.

Rocenib 5mg Tablet is an Janus kinase inhibitor. It works by blocking the action of the enzyme, Janus kinase. This decreases inflammation and joint damage in rheumatoid arthritis.

• Rocenib 5mg Tablet is used alone or in combination with other medicines for the treatment of rheumatoid arthritis, that did not improve with other anti-rheumatic drugs.
• It may take take 3 to 6 months to feel the maximum effect of this medication. Keep taking it as prescribed.
• Your doctor may get regular blood tests done to monitor your liver function, kidney function, blood counts, or cholesterol levels.
• Rocenib 5mg Tablet can make it a bit harder for people to fight off infections. Inform your doctor if you have symptoms of an infection such as fever, chills, cough, and muscle aches.
• Your doctor may get TB (tuberculosis) skin test and a chest X-ray before starting treatment with this medication.
• Inform your doctor if you are pregnant, planning to conceive, or breastfeeding.

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1373-74.

Drugs.com. Tofacitinib. [Accessed 02 Apr. 2019] (online) Available from:

Tofacitinib. New York, New York: Pfizer Labs; 2012 [revised Nov. 2012]. [Accessed 02 Apr. 2019] (online) Available from:

Central Drugs Standard Control Organisation (CDSCO). [Accessed 02 Apr. 2019] (online) Available from: